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converted to AD-dementia after 28.6 ± 19.3 months of follow-up. Expert reading was the most accurate tool to detect these MCI
converters from healthy controls (sensitivity 89.6%, specificity 89.0%, accuracy 89.2%) while two moderately-skilled readers
were less (p < 0.05) specific (sensitivity 85.7%, specificity 79.8%, accuracy 82.3%) and PALZ score was less (p < 0.001) sensitive
(sensitivity 62.3%, specificity 91.7%, accuracy 79.6%). Among the remaining 67 aMCI patients, 50 were confirmed as aMCI
after an average of 42.3 months, 12 developed other dementia, and 3 reverted to normalcy. In 30/50 persistent MCI patients, the
expert recognized the AD hypometabolic pattern. In 13/50 aMCI, both the expert and PALZ score were negative while in 7/50,
only the PALZ score was positive due to sparse hypometabolic clusters mainly in frontal lobes. Visual FDG-PET reads by an
expert is the most accurate method but an automated, validated system may be particularly helpful to moderately-skilled readers
because of high specificity, and should be mandatory when even a moderately-skilled reader is unavailable.
Keywords: Alzheimer’s disease, amnestic mild cognitive impairment, FDG-PET, PALZ score, visual read
INTRODUCTION
18F-fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) has long been recognized as an
accurate biomarker for the diagnosis Alzheimer’s
disease (AD) dementia [1, 2]. The typical ‘AD
hypometabolic pattern’ is well known and mainly
includes the posterior cingulate cortex, precuneus, pos-
terior temporoparietal cortex, and medial temporal
lobe hypometabolism. With different metrics, sensitiv-
ity and specificity above 80% have been consistently
reported in AD dementia [3].
As FDG-PET correlates well with the severity of
cognitive impairment [4], the AD hypometabolic pat-
tern may be less evident at the stage of mild cognitive
impairment (MCI) due to AD and consequently the
sensitivity could be lower. Nowadays, the main ques-
tion is to identify the AD hypometabolic phenotype at
the MCI stage, or even earlier, in order to intervene
promptly and to access clinical trials with disease-
modifying drugs.
Recent FDG-PET data are emerging in MCI cohorts
from large multicenter studies [5–9], with medium-
term follow-up (i.e., 2–3 years), showing variable
sensitivity and specificity, mainly depending on the
metric used to analyze data [3]. In this recent
meta-analysis in pooled 532 MCI patients, average
FDG-PET prognostic sensitivity to the development
of AD dementia, obtained with different metrics,
was 76% and average specificity versus non-converter
patients was 74%. Visual read was the most sensitive
(94%) but the least specific (68%) tool, individual case
analysis with statistical parametric mapping (SPM)
being the most specific (92%) but the second least
sensitive (72%).
However, while diagnostic sensitivity can be easily
computed in MCI converters, specificity computation
versus non-converters is seriously flawed by the lim-
ited time of follow-up in most studies, as it has been
shown that a non-negligible part of MCI patients can
take up to 7 years to convert to dementia [10]. Indeed,
hypometabolism within the AD pattern can be identi-
fied also in the group of non-converter MCI patients
[11–13], especially in those showing cognitive wors-
ening during the follow-up [14].
As for all the other AD biomarkers, one of the main
issues is how FDG-PET images are evaluated and/or
measured. In the above mentioned meta-analysis, the
authors concluded that diagnostic accuracy of imag-
ing biomarkers is at least as dependent on how the
biomarker is measured as on the choice of biomarker
itself [3]. As a matter of fact, FDG-PET scans are
still usually reported visually by nuclear medicine
physicians which introduces another ‘variable in the
equation’ of PET reporting because readers’ expertise
may range widely. On the other side, the automatic or
semi-automatic available tools have a lower inter-rater
variability but some of them, such as the SPM maps,
are not user-friendly and the statistical output maps still
require to be evaluated, especially if few and sparse
hypometabolic clusters are highlighted. Only some
of them are freely available and they are not widely
distributed, especially in nuclear medicine depart-
ments without expertise or specific interest in brain
imaging.
Even more importantly, the direct comparison
between visual read and statistically-assisted interpre-
tation is poorly known in MCI patients. In a recent
paper comparing MCI patients and controls, statistical
surface projection (SSP) software improved specificity
versus visual read while the sensitivity was similar ver-
sus both the beginner and the expert reader [15]. The
FDG-PET guidelines of the European Association of
Nuclear Medicine (EANM) [16] admit the use of both
visual and software-aided approaches, recommending
their combined use but not suggesting further proce-
dural reading guidelines, and a similar position has
been taken by the Society of Nuclear Medicine in its
2009 guidelines. Accordingly, especially in daily clini-
cal practice, the best way of reporting FDG PET scans
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is still a matter of debate and clear statements from
international societies are lacking.
We compared the diagnostic performance of visual
read with that of an automatic tool [17, 18] yielding
a statistical classification of FDG-PET scans in 109
healthy subjects and 142 patients with amnestic MCI
(aMCI) recruited by the European Alzheimer Disease
Consortium (EADC) PET project, followed-up for at
least 2 years or until conversion to dementia.
METHODS
Subjects
Clinical, neuropsychological, and FDG-PET data
derive from the FDG-PET project of the EADC
(http://www.eadc.info/sito/pagine/a 07.php?nav = a),
aimed at joining together data from patients with MCI
and normal controls. Six EADC centers (namely,
Amsterdam, Brescia, Genoa, Marseille, Munich,
Perugia) in four countries participated.
Patients with aMCI with or without impairment in
other cognitive domains and healthy controls have been
enrolled. To date, data from 109 healthy controls and
225 aMCI patients are available, but for the purpose
of the present study, we considered only those aMCI
patients with a clinical follow-up of either at least two
years or until the development of dementia. These were
142 patients whose main demographic and clinical
characteristics are shown in Table 1.
As for aMCI, the inclusion and exclusion criteria
are explained in previous papers [19, 20]. In summary,
they basically included outpatients newly referred for
cognitive complaints to a center dedicated to the eval-
uation of cognitive disorders. Cognitive complaints
mainly included memory complaints but they could
also include difficulties in other cognitive domains,
such as attention and orientation. Main exclusion crite-
ria were dementia; any somatic, metabolic, psychiatric,
or neurological disorder that may cause cognitive
impairment. Dementia was excluded by the clinical
interviews with patients and caregivers that ruled out
significant impairment in activities of daily living, and
by means of the Clinical Dementia Rating (CDR) scale,
scoring 0.5 in all aMCI patients. General cognition was
assessed by means of the Mini-Mental State Examina-
tion (MMSE) in all centers.
All subjects underwent rating scales for depres-
sion and neuropsychiatric symptoms according to
the routine in use in each center. Patients with
major depression, delusions, or hallucinations were
excluded. Structural neuroimaging was mainly per-
formed by means of magnetic resonance imaging
(MRI) while computed tomography (CT) was per-
formed when MRI was unfeasible because of
contraindications or patient intolerance.
Neuropsychological tests were administered in the
domains of memory, language, executive function,
attention, and visuoconstruction, according to the rou-
tine of each center, in order to define the aMCI
syndrome, according to the Petersen’s criteria [21].
Raw scores were converted to age-, education-, and
gender-corrected Z-scores according to locally col-
lected or published normative data in use in each center
that vary among countries and languages. Impairment
was defined as a Z-score of −1.5 or lower. Sub-
jects with impairment in the memory domain only
(single-domain aMCI) or with impairment in the mem-
ory domain plus impairment in non-memory domains
(multidomain aMCI) were defined as aMCI.
The 142 aMCI patients were regularly followed-
up to identify those developing dementia. During this
Table 1
Main demographic and clinical characteristics of 142 patients with aMCI followed-up for at least 2 years (or until the conversion to dementia)
in the EADC-PET project. Values are expressed as mean ± standard deviations
All Converted MCI Converted to Reverted
to AD non-converters other dementia to normal
Number 142 77 50 12 3
Age (y) 72.07 ± 8.20 73.51 ± 8.01 70.04 ± 8.03 72.58 ± 7.89 67.00 ± 11.14
Gender M/F 74/68 33/44 30/20 10/2 1/2
Education (y) 9.64 ± 4.29 9.78 ± 4.33 9.80 ± 4.29 7.33 ± 3.50 12.67 ± 4.51
MMSE (mean ± SD) 26.80 ± 1.98 26.75 ± 2.02 26.82 ± 2.00 26.75 ± 1.54 28.00 ± 2.65
Follow-up (mos) 33.44 ± 19.50 28.62 ± 19.26 42.30 ± 17.18 27.92 ± 21.02 31.33 ± 3.79
Neuropsychological Z scores
Verbal memory Immediate recall −1.19 ± 1.12 −1.45 ± 1.04 −0.87 ± 1.18 −0.95 ± 1.09 −1.19 ± 1.07
Verbal memory Delayed recall −1.68 ± 1.0 −1.88 ± 0.91 −1.51 ± 1.06 −1.32 ± 1.07 −1.23 ± 1.44
Language −0.02 ± 1.47 −0.02 ± 1.68 −0.21 ± 0.18 0.54 ± 1.01 1.22 ± 0.91
Visuoconstruction −0.31 ± 1.62 −0.29 ± 1.64 −0.09 ± 1.41 −1.31 ± 2.06 −0.54 ± 2.17
Attention −0.46 ± 2.71 −0.70 ± 2.27 0.25 ± 3.88 −0.95 ± 1.44 −0.10 ± 1.20
Executive Function −0.87 ± 1.99 −1.24 ± 1.66 −0.03 ± 2.68 −1.08 ± 1.40 −0.31 ± 1.30
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period, patients were carefully treated for systemic
co-morbidity. None of the patients was taking antide-
mentia medication at the time of either PET scan or
during the follow-up period, until a formal diagnosis
of AD-dementia was made.
Diagnosis of dementia was established according to
the criteria in use at the beginning of the study. Demen-
tia of the AD type was diagnosed according to the
National Institute of Neurological and Communicative
Disorders, Stroke, Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria
[22] and to the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV R) criteria. Diagno-
sis of frontotemporal lobar degeneration (FTLD) and
dementia with Lewy bodies (DLB) was formulated
according to the Neary et al. [23] and McKeith et al.
[24] criteria, respectively.
Healthy controls recruited by the same EADC cen-
ters have been described in previous papers [19, 20].
Briefly, they were volunteers undergoing the same
clinical and neuropsychological evaluation as patients
and were not taking neuropsychoactive drugs or drugs
known to interfere with cerebral metabolism. Only sub-
jects with a MMSE score >26 and a CDR = 0 were
included. There were 109 subjects, 53 males and 56
females, mean age 67.0 ± 6.6 years, mean MMSE
score: 29.3 ± 1.0, mean education: 11.4 ± 4.0 years.
Their healthy status was checked again with a clini-
cal interview about one year later (mean: 11.8 ± 4.8
months).
Subject information and scans uploaded by each
center were as follows: Amsterdam, 16 patients and 20
controls; Brescia, 43 patients and 27 controls; Genoa,
40 patients and 33 controls; Marseille, 9 patients and 10
controls; Munich, 34 patients and 19 controls; at the
time of this data analysis, Perugia had not uploaded
cases yet.
The study was carried out in accordance with the
content of the Helsinki declaration and was approved
by the local Ethics Committees; all subjects provided
written informed consent.
PET procedures
FDG-PET was performed within 2 months from
the baseline clinical-neuropsychological examination
according to the EANM guidelines in use when the
study began [25]. Subjects fasted for at least 6 h.
Before radiopharmaceutical injection, blood glucose
was checked and was <140 mg/dL in all subjects. Sub-
jects were injected with 185–250 MBq of 18F-FDG
via venous cannula. Required minimum time interval
between injection and scan start was 30 min. Required
minimum scan duration was 10 min. Emission scans
were acquired in 3-dimensional mode. Images were
reconstructed using an ordered subset expectation
maximization (OSEM) algorithm in all centers but
Amsterdam (filtered backprojection). Attenuation cor-
rection was based on CT scan in Brescia, Genoa, and
Marseille, and on transmission scan in Munich and
Amsterdam. Scatter correction was performed using
standard software as supplied by scanner manufac-
turers. Technical details of the scanners used in the
different centers are reported in previous papers [19,
20]. Anonymous scans and clinical information were
uploaded in a dedicated safe file transfer protocol
web site.
Image analysis
Our aim was to compare the ability of moderately-
skilled readers, an expert reader, and an automatic
voxel-based analysis method. In order to reproduce
‘the real world’ of FDG-PET reporting, we imagined
two conditions, i.e., one expert reporting alone and
two moderately-skilled readers reporting together and
reaching a final common opinion. We choose not to
test the performance of a beginner reader because we
believe that recognizing subtle metabolic abnormali-
ties in such a clinical context cannot be faced by a
beginner left alone. Also, we chose not to evaluate
the incremental diagnostic value of PALZ score with
respect to qualitative readings because we wanted to
directly compare the two reading systems and obtain
accuracy values for both, which is poorly known in
MCI patients, prior to evaluate in another series the
incremental value of the automatic system to visual
reads.
Then, we first defined a ‘moderately-skilled’ reader
as a nuclear medicine physician with about a 3-year
experience in weekly reporting of FDG-PET scans and
a total of about 500 scans commented and reported
together with an expert. Secondly, we defined an
‘expert’ reader one with at least 10-year experience
in weekly reporting of FDG-PET scans and with sus-
tained scientific activity in the field. We then identified
one expert and two moderately-skilled readers, the
latter reading the scans together and were forced to
reach a consensus. All raters read the 251 scans (142
patients and 109 controls) without any other infor-
mation and forced to a dichotomous reading, i.e.,
Alzheimer hypometabolic pattern present or absent.
Only when the Alzheimer pattern was absent, then
the readers were invited to express whether another
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hypometabolic pattern could be identified, includ-
ing the FTLD and the DLB pattern. The Alzheimer
pattern was defined according to the large literature
evidence and included hypometabolism in at least one
of the following: posterior cingulate cortex, precuneus,
posterior temporoparietal cortex, and medial tempo-
ral lobe. The FTLD pattern included at least one of
the following: orbitofrontal cortex, dorsolateral frontal
cortex, ventrolateral frontal cortex, anterior temporal
lobe, insula, and anterior cingulate cortex. The DLB
pattern included the Alzheimer pattern without nec-
essarily the medial temporal lobe but with the lateral
occipital cortex.
The PMOD software (PMOD technologies,
http://www.pmod.com) was used for automatic,
voxel-based evaluation of scans with the ‘Alzheimer’
option computing the ‘Probability of ALZheimer’
or PALZ score. The PALZ score is a voxel-based
parametric mapping method yielding diagnostic
information on brain regions that are typically
affected in AD [17]. Individual FDG-PET images
are compared to a fixed database of normal elderly
scans through a voxel-wise t-test, including age as
confounding variable. The PALZ score is computed
as voxel-by-voxel sum of t-scores in a pre-defined
AD-pattern mask. PALZ was developed to distinguish
AD from healthy controls above 50 years of age.
The threshold for abnormality was set at 11,090
(t-sum higher than 11,090 = abnormal FDG-PET). As
some centers provided Dicom files and some others
provided Analyze files, Dicom files were converted to
Analyze format. In fact, the use of different formats
gives rise to slight differences in PALZ scores, as
already outlined in a previous paper [6]. With analyze
format, images must be checked for correct display
orientation and eventually reoriented to anatomic
position, preliminary to PALZ score computation.
Statistics
Confidence intervals (CI) for sensitivity, specificity,
accuracy, positive (PPV) and negative (NPV) pre-
dictive values were computed by using the Wald
interval for binomial proportions [26]. CI for posi-
tive (+LR) and negative (−LR) likelihood ratios were
computed according to Simel et al. [27], while CI
for the odds ratio were computed by the conven-
tional log-transform method [28]. Paired comparisons
between classifiers for sensitivity, specificity, and accu-
racy were performed by Mc Nemar binomial test.
Paired comparison between classifiers for PPV and
NPV was performed according to the generalized score
statistic proposed by Leisenring et al. [29]. Paired com-
parisons between classifiers for +LR and –LR were
performed by the evaluation of log-transformed LR
according to Nofuentes & Del Castillo [30]. Paired
comparisons between classifiers for odds ratio were
performed by evaluating conditional relative odds
ratio, based on McNemar’s odds ratio, according to
the method described by Suzuky [31]. Receiver oper-
ating characteristic comparison was unfeasible due to
the dichotomous output of visual reading.
RESULTS
Follow-up diagnosis
During the follow-up period (mean in the 142
patients: 33.4 ± 19.5 months, range: 6–98), 77 patients
(54.2%) progressed to AD dementia (‘prodromal AD’
patients, pAD), 10 patients (7%) developed FTLD, 2
patients progressed to DLB, and 3 patients reverted
to a normal condition. The remaining 50 patients were
confirmed to have aMCI at the last available follow-up,
ranging from 24 to 98 months (details in Table 1).
Control group
The AD-hypometabolic pattern was seen in 22
healthy subjects by the moderately-skilled readers
(79.8% specificity), in 12 subjects by the expert (89%
specificity) while the PALZ score yielded a statisti-
cally significant result in 9 controls (91.7% specificity).
Specificity was significantly higher for either the expert
or PALZ score than for the moderately-skilled readers
(p < 0.05) but did not differ between expert and PALZ
score. Concordance between the two visual reading
systems was 78%, between the expert and PALZ score
was 84.4%, and between the moderately-skilled read-
ers and PALZ score was 75.2%. Figure 1 shows an
example of a negative PALZ score in a control subject
in whom the AD hypometabolic pattern was erro-
neously recognized by the moderately-skilled readers.
MCI patients who later converted to AD dementia
(prodromal AD, pAD)
The conversion to AD dementia in these 77 patients
was fixed as the ‘gold standard’ to evaluate sensitiv-
ity of different PET readings. The moderately-skilled
readers, the expert, and the PALZ score identified
the AD hypometabolic pattern in 85.7%, 89.6%, and
62.3% of patients, respectively. Sensitivity was higher
for both expert (p < 0.001) and moderately-skilled
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Fig. 1. Example of false positive reading with the moderately-skilled readers. The AD hypometabolic pattern was erroneously recognized by
the moderately-skilled readers in a 62 year-old male control subject with a normal PALZ score (T-sum within AD regions: 8,044). On top,
FDG-PET visual analysis discloses very mild and sparse asymmetries in frontal-insular and inferior parietal regions (left minus) and in superior
parietal region (right minus) (higher to lower uptake in white, red, yellow, green, and blue colors in decreasing order). On bottom, statistical
maps obtained by means of the PMOD software showing very small and sparse significant hypometabolic clusters (in red).
Fig. 2. Example of false negative reading with the T-sum score. The AD hypometabolic pattern was recognized by the expert while the PALZ
score was not significantly increased in a 72 year-old man converted to AD-dementia after 40 months of follow-up. On top, FDG-PET visual
analysis discloses moderately reduced uptake in left temporo-parietal cortex while the statistical PMOD maps (on bottom) shows significant
hypometabolic clusters in bilateral temporal regions and left parietal cortex without reaching the statistical threshold (T-sum = 7,225). Other
details as in Fig. 1.
readers (p < 0.01) than for PALZ score while did not
significantly differ between the two visual readings.
Concordance between the two visual readings was
88.3%, between the expert and PALZ score was 62.3%,
and between the moderately-skilled readers and PALZ
score was 63.6%. In three patients, neither the expert
nor the PALZ score were consistent for the presence of
an AD hypometabolic pattern. Fig. 2 shows an exam-
ple of a negative PALZ score in a patient in whom
the AD hypometabolic pattern was recognized by the
expert. In summary, total accuracy of moderately-
skilled readers, expert and T-sum was 82.30%, 89.25%,
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Table 2
Summary of FDG-PET analysis in 77 patients with aMCI and 109 controls from the EADC-PET project
Moderately-skilled readers Expert reader PALZ score
Sensitivity (95% C.I.) 0.857 (0.755–0.923)++ 0.896 (0.800–0.951) 0.623 (0.505–0.729)∗∗∗
Specificity (95% C.I.) 0.798 (0.708–0.867)+∗ 0.890 (0.812–0.939) 0.917 (0.845–0.959)
Total accuracy (95% C.I.) 0.823 (0.760–0.874)∗ 0.892 (0.839–0.933) 0.796 (0.731–0.851)∗
Positive predictive value (95% C.I.) 0.750 (0.644–0.833)∗ 0.852 (0.752–0.918) 0.842 (0.716–0.921)
Negative predictive value (95% C.I.) 0.888 (0.804–0.940)++ 0.924 (0.851–0.964) 0.775 (0.691–0.842)∗∗∗
+Likelihood ratio (95% C.I.) 4.25 (2.89–6.24)∗ 8.14 (4.75–13.96) 7.55 (3.94–14.45)
−Likelihood ratio (95% C.I.) 0.18 (0.10–0.31)++ 0.12 (0.06–0.23) 0.41 (0.31–0.55)∗∗∗
Odds ratio (95% C.I.) 23.73 (10.75–52.35) 69.7 (27.06–179.62) 18.39 (8.07–41.89)∗
Z value 7.84 8.79 6.93
∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05 in the comparison between either moderately-skilled readers or PALZ score and the expert
reader.++p < 0.01; +p < 0.05 in the comparison between moderately-skilled readers and PALZ score. Nominal probability levels,
uncorrected for multiple comparisons. See the Statistics section in the Methods for statistical method details.
and 79.57%, respectively. Table 2 summarizes the
results and reports positive (PPV) and negative (NPV)
predictive values, positive (+LR) and negative (−LR)
likelihood ratio, and odds ratio for the three reading
systems.
Patients with persistent MCI at follow-up
FDG-PET scan reading in persistent MCI group
without a definite clinical outcome was faced by con-
sidering the best figures of sensitivity and specificity
reached in the 77 pAD patients and in the 109 con-
trols, i.e., the expert reading was the gold-standard for
sensitivity and the concordance of both expert reading
and PALZ score was the gold-standard as for speci-
ficity. In fact, specificity values reached by experts
and PALZ score were very similar. We thus identified
a group of aMCI patients likely expressing the AD
hypometabolic pattern based on the expert’s score and
a group of patients in whom the AD hypometabolic
pattern was unlike based on the concurring negative
evaluation of the expert and of PALZ score. The expert
identified the AD-hypometabolic pattern in 30 patients
(aMCIExp+) (Fig. 3 shows a patient with a positive
PALZ score also) while both the expert and the PALZ
score were negative in 13 cases (aMCIExp-/PALZ-). In
the remaining 7 patients, the PALZ score was positive
but the expert did not identify the AD-hypometabolic
pattern (aMCIExp-/PALZ+) (example in Fig. 4).
Table 3 reports the main data for the 30 aMCI-
Exp +and 13 aMCIExp-/PALZ- subgroups. Briefly, the
two subgroups did not show significant differences for
Fig. 3. Example of AD hypometabolic pattern recognized by the expert and with a positive PALZ score (T-sum = 12,628) in a 64 year-old man
with persistent aMCI after a 40-month follow-up. On top, FDG-PET visual analysis shows moderately reduced uptake in the left temporo-parietal
cortex. On bottom, statistical PMOD maps also shows significant clusters within the AD hypometabolic pattern in left temporo-parietal cortex
and right parietal cortex. Other details as in Fig. 1.
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Fig. 4. Example of absence of AD hypometabolic pattern according to the expert but with a positive PALZ score (T-sum = 15,180) in a 79
year-old woman with persistent aMCI after a 42-month follow-up. On top, FDG-PET visual analysis does not clearly show reduced uptake in
the typical AD regions. On bottom, statistical PMOD maps shows significant hypometabolic clusters sparsely distributed in bilateral frontal and
temporal lobes, the anterior cingulate cortex, right cuneus and posterior cingulate cortex, and left parietal lobe. Other details as in Fig. 1.
Table 3
Main clinical characteristics in the two main subgroups of patients with persistent MCI at follow-up
aMCIExp+ aMCIExp-/PALZ- p value
Number 30 13
Age (y; mean ± SD) 69.7 ± 8.69 69.1 ± 7.70 n.s.
Gender M/F 22/8 6/7 n.s.
Education (y; mean ± SD) 10.0 ± 4.75 10.5 ± 3.26 n.s.
PALZ (T-sum score; mean ± SD) 20359.53 ± 15799.30 4993.47 ± 3248.69 <0.001
Basal MMSE (mean ± SD) 26.77 ± 1.74 27.78 ± 2.28 n.s.
Follow-up MMSE (mean ± SD) 24.43 ± 2.18 26.15 ± 3.56 <0.05
Follow-up length (mo; mean ± SD) 41.67 ± 16.67 44.23 ± 21.89 n.s.
aMCIEXP+, patients in whom the expert identified the AD hypometabolic pattern; aMCIExp-/PALZ-, patients in whom
neither the expert nor the PALZ score identified an AD hypometabolic pattern. PALZ (T-sum score), number of voxels in
the AD hypometabolic regions as identified by the automated analysis of PALZ.
the main demographic characteristics, MMSE score
at baseline and for the length of follow-up while at
follow-up the MMSE score was lower (p < 0.05) in
the 30 aMCIExp+ than in the 13 aMCIExp-/PALZ-
subgroup.
MCI patients converted to FTLD, DLB,
or reverted to normal condition
We did not include in the statistical analysis the find-
ings in these small subgroups, but rather reported them
with descriptive purposes because the PALZ score has
been developed and validated to differentiate between
AD and healthy controls, not other dementia. Notwith-
standing, the frontal association cortex and some areas
of the anterolateral temporal cortex fall within the
PALZ computation so that even in FTLD patients the
PALZ can give a pathological result. Keeping this in
mind, a specific FTLD pattern was concordantly rec-
ognized in 9 out of 10 FTLD patients by both the
moderately-skilled readers and the expert (90% sensi-
tivity), and in 6 of them the PALZ score was positive.
The two DLB patients were concordantly read as with
a DLB pattern by all readers and the PALZ score was
positive. Among the three subjects reverted to a nor-
mal condition, the moderately-skilled readers reported
a normal scan in one, the expert in two while the PALZ
score was normal in all the three subjects.
DISCUSSION
This study shows that visual read of FDG-PET is
quite sensitive in identifying the AD hypometabolic
pattern in aMCI patients who later converted to AD
dementia, if adequate training and expertise is pro-
vided. Sensitivity was slightly but not significantly
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lower in the moderately-skilled readers than in expert
reader while was significantly lower for PALZ score.
Thus the trained reader can pick-up subtle abnor-
malities that do not reach the threshold of statistical
significance set for the T-sum score. This better sensi-
tivity can be due to several factors, including the ability
of the skilled reader to highlight inter-hemispheric
asymmetries in critical areas, a feature that is not
available in the PALZ scoring system, or by other
voxel-based statistical mapping system, such as SPM.
Only very recently some automatic tools for the
analysis of FDG-PET in dementia have embedded
asymmetry computation [32]. Evaluation of asymme-
tries was already regarded as a very sensitive approach
to detect abnormalities in brain function in dementia
[33] and in cerebrovascular disease [34]. Indeed, eval-
uation of asymmetries is among the cornerstones of
reader training in specialized centers and one of the
main index on which the expert reader bases his/her
evaluation. In milder cases, such as aMCI patients, a
metabolic asymmetry can be highlighted by the visual
reading but either the relatively hypometabolic region
may be not large enough or the hypometabolism may
be not severe enough to reach the statistical thresh-
old on PALZ score. On the other hand, the PALZ score
sensitivity was set based on patients with AD dementia
and even if it has been shown to reach 83% in very mild
AD patients [17] and 85% in mild AD [18], it has not
been specifically trained and validated in prodromal
AD patients (i.e., aMCI patients later converted to AD
dementia). Indeed, few data have dealt with sensitiv-
ity of PALZ score in MCI converter patients showing a
sensitivity of 57% in 30 MCI converter patients coming
from the ADNI database [18] and of 79% in 14 MCI
converter patients in a naturalistic population [35].
Thus, the present series of MCI converter patients is the
largest ever assessed with the PALZ score. A similar
phenomenon has been verified for an MRI automatic
analysis method measuring temporal atrophy that was
less accurate in distinguishing between MCI convert-
ers and non-converters when the tool was trained in
AD-dementia patients versus controls rather than in
MCI converters versus non-converters [36].
Sensitivity of FDG-PET between 80% and 90%
in prodromal AD patients has been recently found
in other cohorts with different metrics. Landau et al.
[37] reported 82% sensitivity with region of interest
analysis in critical regions in 28 patients with MCI
due to AD from the ADNI database, followed for
12–36 months (mean 21). In the study by Shaffer et al.
[7] in 43 patients with MCI due to AD, sensitivity
by means of principal component analysis was 86%.
Using a ‘hypometabolic convergence index’, sensitiv-
ity of 81.8% was found in 36 MCI ADNI patients
converted to AD dementia in 18 months [5]. A recent
meta-analysis pooling 532 MCI patients described in
10 studies reported a mean sensitivity of 76%, obtained
with different metrics, but in particular the sensitivity
reached with visual read was 94%, thus close to the
figure obtained in our study [3].
Instead, specificity was fairly good especially with
the PALZ score, slightly lower with the expert but
significantly lower with the moderately-skilled read-
ers. The 91.7% specificity is close to the high figure
reported in previous studies with the PALZ score,
comparing AD patients and controls, ranging between
78.4% and 94.4% [17, 18, 38]. The moderately-skilled
reader tends therefore to overemphasize minimal
changes that are part of the between-subject variability
in brain function. Thus, only the expert could rea-
sonably avoid the assistance of the automatic system
while the moderately-skilled readers may take advan-
tage of it to improve specificity. We choose not to test
the ‘beginner’ reader, but the results obtained in the
moderately-skilled readers strongly suggest that the
assistance of an automatic and validated reading sys-
tem is mandatory for beginners who cannot access an
expert-guided reader training and have not completed
a relevant number of scans reported with supervi-
sion. The significant support of an automatic system to
visual reading for moderately-skilled readers is in sub-
stantial agreement with the few other papers assessing
this issue in smaller groups. In 39 AD patients and 40
subjects without AD, 3D-SSP significantly improved
accuracy of novice readers allowing them to score simi-
larly as expert readers, but 3D-SSP did not significantly
improve the performance of experts which was already
rather high [39]. In another paper in 30 AD patients
and 30 controls, adopting volumes of interest anal-
ysis as derived by 3D-SSP, experts performed better
than beginners and the automatic analysis significantly
improved beginner performance in the 15 patients with
late-onset AD, but not expert performance [40]. The
only other available paper in MCI concerned a group
of 18 patients and showed that 3D-SSP increased speci-
ficity, but not sensitivity, of both beginner and expert
readers [15].
An intriguing part of this study concerns the 50
patients still in an aMCI stage after a mean time of
3 years and a half since the first evaluation. We know
that either these patients have been assessed very early
on the path of AD evolution (late converters) or they
have MCI not related to a neurodegenerative disease.
In thirty of them, the expert identified the typical AD
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hypometabolic pattern, thus suggesting that FDG-PET
can pick up the AD phenotype at least 3.5 years in
average before the onset of AD dementia. Indeed, the
MMSE score at the last available follow-up was lower
in this subgroup than in the 13 patients with a normal
FDG-PET, confirming the ongoing decline although
not yet reaching the clinical stage of dementia. These
data are in keeping with the findings in familial [41]
and sporadic [5–9, 12–14] AD and are in line with the
biomarker temporal cascade hypothesis as proposed
by Jack et al. [42, 43], suggesting that FDG-PET can
disclose the AD hypometabolic pattern several years
before the onset of cognitive symptoms. Furthermore,
they are in accordance with the data suggesting that the
impact of FDG-PET is particularly useful in the man-
agement of those patients with less severe cognitive
impairment [44].
Conversely, in 13 out of these 50 patients both the
two most specific reading systems, i.e., the expert and
PALZ score, were negative strongly suggesting that
their MCI syndrome was not related to a neurode-
generative disease. Several factors can affect cognitive
tests over time, such as low socioeconomic level [45]
and small vessel cerebrovascular disease [46], which
were not specifically addressed in this study. In seven
patients, the PALZ score was positive but the expert
did not recognize the AD hypometabolic pattern. The
interpretation of this unexpected result, given the lower
sensitivity and the paired specificity of PALZ score
as compared to the expert, seems to rely in the pecu-
liar construct of PALZ score that includes several
areas in the frontal lobes as pertaining to the AD-
hypometabolic pattern (Fig. 4). However, the expert
interprets frontal hypometabolism as potentially due
to AD only if temporoparietal hypometabolism can be
concomitantly visualized, an operation not performed
by the PALZ score computation. The peculiar results
obtained in these seven patients highlight another prob-
lem, the statistical maps obtained at individual level
through PMOD or by other automatic systems, such as
SPM, that need eventually to be interpreted.
It is worth noting that 12 patients converted to FTLD
or DLB, and FDG-PET visual reading was consistent
with the diagnosis in all but one patient. This result
is in keeping with the notion that, although aMCI
patients are more prone to convert to AD demen-
tia, they can develop other types of dementia [47].
This finding underlines that the adequate knowledge of
hypometabolic patterns associated with different types
of dementia (obtained either visually or by means of
a software-generated map) is mandatory for the final
interpretation of scans [48]. This subgroup of patients
further proves the unbroken role of FDG-PET in aMCI
patients even in the era of amyloid PET. By exploring
the topographical distribution of hypometabolism in
a large spectrum of diseases, FDG-PET can improve
diagnostic accuracy at a time when the clinician needs
to know whether his/her patient with aMCI is actually
affected by a neurodegenerative disease by identifying
a specific hypometabolic pattern [2].
Some limitations of this study should be acknowl-
edged. These aMCI patients were recruited at
specialized centers and therefore conclusions may not
be generalized in the whole MCI population. In fact, the
conversion rate to dementia was high (26% per year)
but it has been shown that patients with aMCI have a
higher conversion rate than the general population of
MCI, including patients with non-amnestic MCI [49].
We do not have histopathological verification of the
clinical diagnoses, or demonstration of brain amyloi-
dosis by means of PET imaging or decreased A1–42
in cerebrospinal fluid (available only in a small sub-
group). Although we considered only those patients
with at least two years of follow-up (unless they con-
verted to dementia before), the follow-up time was not
homogeneous. Finally, data were acquired by different
PET scanners although we tried to minimize this het-
erogeneity by including balanced numbers of patients
and controls from each center.
In conclusion, this study has shown that FDG-PET
is an accurate biomarker of AD-type neurodegenera-
tion in a large series of aMCI patients later converting
to AD dementia and in healthy controls. Even more
important, it can pick up the presence or absence of
an AD phenotype in a subgroup of aMCI patients not
yet converted to dementia after a mean follow up of
more than three years. Visual reads by an expert is the
most accurate method but an automated, validated sys-
tem may be particularly helpful to moderately-skilled
readers especially because of its high specificity, and
should be mandatory when even a moderately-skilled
reader is unavailable.
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